Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with β thalassemia intermedia-Reference-Cited by-同舟云学术

Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with β thalassemia intermedia

Published:2011-12 Issue:4 Volume:47 Page:232-234
ISSN:1079-9796
Container-title:Blood Cells, Molecules, and Diseases
language:en
Short-container-title:Blood Cells, Molecules, and Diseases

Author:

Musallam Khaled M.,Taher Ali T.,Duca Lorena,Cesaretti Claudia,Halawi Racha,Cappellini Maria Domenica

Publisher

Elsevier BV

Subject

Cell Biology,Hematology,Molecular Biology,Molecular Medicine

Reference18 articles.

1. Disorders of hemoglobin: genetics pathophysiology, and clinical management;Steinberg,2009

2. Optimal management of beta thalassaemia intermedia;Taher;Br. J. Haematol.,2011

3. Age-related complications in treatment-naive patients with thalassaemia intermedia;Taher;Br. J. Haematol.,2010

4. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study;Taher;Blood,2010

5. Liver iron concentrations and urinary hepcidin in beta-thalassemia;Origa;Haematologica,2007

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anemia and iron overload as prognostic markers of outcomes in β-thalassemia;Expert Review of Hematology;2024-07-26

2. The Exploring of Growth Differentiation Factor-15 and H63D Gene Polymorphisms in β-thalassemia Major: Implications for Cardiovascular Risk and Iron Overload;Journal of Applied Hematology;2024-01

3. The association of growth differentiation factor-15 levels and osteoporosis in patients with thalassemia;The American Journal of the Medical Sciences;2023-08

4. Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy;Drug Design, Development and Therapy;2023-05

5. Clinical Complications and Their Management;Hematology/Oncology Clinics of North America;2023-04